Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: The CLARICOR trial
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease : The CLARICOR trial. / Bjerre, Mette; Hilden, Jørgen; Kastrup, Jens; Skoog, Maria; Hansen, Jørgen F; Kolmos, Hans J; Jensen, Gorm B; Kjøller, Erik; Winkel, Per; Flyvbjerg, Allan; Gluud, Christian; CLARICOR Trial Group.
In: Scandinavian Journal of Clinical & Laboratory Investigation, Vol. 74, No. 8, 11.2014, p. 657-664.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease
T2 - The CLARICOR trial
AU - Bjerre, Mette
AU - Hilden, Jørgen
AU - Kastrup, Jens
AU - Skoog, Maria
AU - Hansen, Jørgen F
AU - Kolmos, Hans J
AU - Jensen, Gorm B
AU - Kjøller, Erik
AU - Winkel, Per
AU - Flyvbjerg, Allan
AU - Gluud, Christian
AU - CLARICOR Trial Group
PY - 2014/11
Y1 - 2014/11
N2 - OBJECTIVES: To elucidate the prognostic power of serum osteoprotegerin (OPG) in patients with stable coronary artery disease (CAD).METHODS: Serum OPG levels were measured in the CLARICOR trial cohort of 4063 patients with stable CAD on blood samples drawn at randomization. The follow-up was 2.6 years for detailed cardiovascular events and 6 years for all-cause mortality.RESULTS: OPG levels were significantly increased in non-survivors (21%) compared to survivors (median [quartiles] 2092 ng/L [1636; 2800] compared to 1695 ng/L [1322; 2193, p < 0.0001]). The 2.6-year follow-up showed that OPG adds to the prediction of both cardiovascular and all-cause mortality in combination with clinical risk factors (HR [one log10 unit increase] 6.1 [95% CI 2.4-15.6, p = 0.0001]) and HR 6.5 [95% CI 3.4-12.5, p < 0.0001], respectively). Similar, in the 6-year follow-up, OPG was found to be a strong predictor for all-cause mortality. Importantly, OPG remained an independent predictor of mortality even after adjustment for both clinical and conventional cardiovascular risk markers (HR 2.5 [95% CI 1.6-3.9, p < 0.0001]).CONCLUSIONS: Serum OPG has a long-lasting independent predictive power as to all-cause mortality and cardiovascular death in patients with stable CAD.
AB - OBJECTIVES: To elucidate the prognostic power of serum osteoprotegerin (OPG) in patients with stable coronary artery disease (CAD).METHODS: Serum OPG levels were measured in the CLARICOR trial cohort of 4063 patients with stable CAD on blood samples drawn at randomization. The follow-up was 2.6 years for detailed cardiovascular events and 6 years for all-cause mortality.RESULTS: OPG levels were significantly increased in non-survivors (21%) compared to survivors (median [quartiles] 2092 ng/L [1636; 2800] compared to 1695 ng/L [1322; 2193, p < 0.0001]). The 2.6-year follow-up showed that OPG adds to the prediction of both cardiovascular and all-cause mortality in combination with clinical risk factors (HR [one log10 unit increase] 6.1 [95% CI 2.4-15.6, p = 0.0001]) and HR 6.5 [95% CI 3.4-12.5, p < 0.0001], respectively). Similar, in the 6-year follow-up, OPG was found to be a strong predictor for all-cause mortality. Importantly, OPG remained an independent predictor of mortality even after adjustment for both clinical and conventional cardiovascular risk markers (HR 2.5 [95% CI 1.6-3.9, p < 0.0001]).CONCLUSIONS: Serum OPG has a long-lasting independent predictive power as to all-cause mortality and cardiovascular death in patients with stable CAD.
U2 - 10.3109/00365513.2014.930510
DO - 10.3109/00365513.2014.930510
M3 - Journal article
C2 - 25026506
VL - 74
SP - 657
EP - 664
JO - Scandinavian Journal of Clinical & Laboratory Investigation
JF - Scandinavian Journal of Clinical & Laboratory Investigation
SN - 0036-5513
IS - 8
ER -
ID: 135186856